In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease.
Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. (tipranks.com)
Analyst...
This indicator may be signaling that ESPR's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. Tickeron's A.I.dvisor backtested 94 similar cases where ESPR's Momentum Indicator exceeded 0, and 81 of them led to a successful outcome. Odds of Success: 86%....
This indicator may be signaling that ESPR's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. Tickeron A.I.dvisor backtested 96 similar cases where ESPR's Momentum Indicator exceeded 0, and 84 of them led to a successful outcome. Odds of Success: 88%....
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul...
I just started playing with FDA approvals using my pendulum. I don't see anything good coming out of this news event other than a bounce to sell into.
Symmetry support is $57.15 held once. Will it twice??
If it doesn't hold this 786 fib (53.99), the door is open to $40.
ESPR: Esperion Therapeutics, Inc.
2020-02-26 17:30:10
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
ESPR: Esperion Therapeutics, Inc.
2020-02-21 16:38:10
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
BE CAREFUL!!
I'm getting bad vibes on the news for tomorrow in this one. This is based on my dowsing work and it suggests a drop of 38%. That would rock it down to about $42.50
FYI I don't know anything about the fundamentals or background on this pending approval, and I really don't know anything about the company, nor do I care.
I'm not super confident yet in...
I took this position yesterday when it broke back above the handle line on this near textbook Cup with Handle pattern (it's a little deep, but I still like it)... My stop is $46, Entry $52.55. My first target is the last high of $60 then on to it's all time high around $80... Ideas, Not investing / trading advice.
Not Financial Advice:
Biggest thing to watch is the small squeeze taking place that should send it further down. Time will tell if they announce any breakthroughs.
NASDAQ:ESPR
Future Catalyst:
October 2018 10/31/2018
Phase 3 data due October, 2018.
Market cap: 1.2B. Float: 24.25M
Company Notes - Negative income, 57 employees, 0 debt, 14% Inst owned, mixed analysis opinion.
50/50 split bulls/bears- I'm suspecting this will continue to bounce a little of its multiple bottom and have some natural longs take this stock up...
